TRL-TAG2-1: A Drug Target / Disease Biomarker (G100189151)
TRL-TAG2-1: A Drug Target / Disease Biomarker
TRL-TAG2-1 is a drug target and a biomarker that is being studied for its potential role in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. TRL-TAG2-1 is a transmembrane protein that is expressed in many different tissues and cells in the body. It is a key regulator of the T-cell receptor (TCR), which is a critical signaling system that helps the immune system recognize and respond to foreign substances in the body.
One of the main functions of TRL-TAG2-1 is to regulate the activity of T cells, which are a critical part of the immune system. T cells are responsible for recognizing and responding to threats such as viruses, bacteria, and cancer cells. When a T cell encounters a foreign substance, it is able to recognize it through the TCR, which is a protein that is expressed in the surface of the T cell. The TCR helps the T cell determine whether the foreign substance is dangerous and should be eliminated.
TRL-TAG2-1 plays a key role in regulating the activity of T cells by helping them to recognize and respond to foreign substances. It does this by interacting with a protein called CD28, which is also a key regulator of the TCR. CD28 helps to stimulate the T cell to divide and become activated, which is necessary for it to be able to recognize and respond to foreign substances.
In addition to its role in regulating T cell activity, TRL-TAG2-1 is also being studied for its potential as a drug target. This is because it is involved in many different signaling pathways that are involved in the development and progression of various diseases. For example, TRL-TAG2-1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. It is also being investigated as a potential therapeutic for cancer, with studies showing that it may be able to inhibit the growth of cancer cells.
Overall, TRL-TAG2-1 is a drug target and biomarker that is being studied for its potential role in treating a variety of diseases. Its ability to regulate T cell activity and its involvement in multiple signaling pathways make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the potential of TRL-TAG2-1 as a drug and to determine its effectiveness in treating various diseases.
Protein Name: TRNA-Leu (anticodon TAG) 2-1
More Common Targets
TRMT13 | TROAP | TRP-AGG6-1 | TRPC7-AS1 | TRPM4 | TRPM7 | TRPV3 | TSC22D3 | TSFM | TSNAX-DISC1 | TSPAN1 | TSPAN2 | TSPAN3 | TSPAN32 | TSPAN5 | TSPEAR | TSPEAR-AS1 | TSPO | TSPOAP1-AS1 | TSSC4 | TSTD1 | TSTD3 | TTC21A | TTC21B-AS1 | TTC24 | TTC3-AS1 | TTC34 | TTLL1-AS1 | TTLL8 | TTLL9 | TTN-AS1 | TUBA1B-AS1 | TUBB2BP1 | TUBB8P7 | TUNAR | TVP23C-CDRT4 | TWIST2 | TXLNB | TXN | TXNL1P1 | TXNP6 | TYMP | U2AF1L4 | UBA2 | UBAC2-AS1 | UBASH3A | UBD | UBDP1 | UBE2CP3 | UBE2D3P1 | UBE2DNL | UBE2F-SCLY | UBE2FP1 | UBE2J2 | UBE2K | UBE2Q2P11 | UBE2Q2P13 | UBE2Q2P16 | UBE2Q2P2 | UBE2V1P9 | UBE2V2P1 | UBL3 | UBL4B | UBL5P3 | UBOX5-AS1 | UBR1 | UBTFL2 | UBXN2A | UCHL1-DT | UCKL1-AS1 | UGDH-AS1 | UGT1A1 | UGT1A10 | UGT1A3 | UGT1A4 | UGT1A5 | UGT1A6 | UGT1A7 | UGT1A8 | UGT1A9 | UGT2B27P | UGT2B28 | UGT2B29P | UGT3A2 | ULK4P2 | UNC93A | UPK1A-AS1 | UPK3BL1 | UQCRC2P1 | UQCRFS1P1 | URAHP | URGCP-MRPS24 | USH1C | USP12-AS1 | USP12-DT | USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P